Proceedings of 32nd Annual General Meeting of the Company held on Monday, 29th September, 2025 at 11:30 A.M. and concluded on 12:40 P.M.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ishita Drugs & Industries held its 32nd AGM on 29th September 2025 at Hotel Krsna Lila, Sanand, Gujarat, from 11:30 AM to 12:40 PM, attended by 34 members in person. Seven resolutions were transacted, including adoption of the audited financial statements for FY ended 31st March 2025, re-appointment of Mrs. Abha Agrawal as Director (retiring by rotation), appointment of statutory auditors for FY 2025-26, and re-appointment of Mr. Arvind Vilasrao Sapkal as Non-executive Independent Director via special resolution. The company also sought shareholder approval for related-party transactions with Ishita Pharmaceuticals and Anvi Lifesciences Private Limited, and appointed Meenu Maheshwari & Associates as Secretarial Auditor. E-voting was conducted via NSDL from 26–28 September 2025, with consolidated results to be declared within 48 hours.
This is a routine compliance filing with no major surprises — no dividend, fundraising, or leadership change beyond standard re-appointments. Shareholders should look out for the scrutinizer's report for final voting results, but the immediate stock price impact is expected to be neutral.